+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma



Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma



Oncology Letters 8(1): 464-466



This study presents a case of metastatic sarcomatoid renal cell carcinoma (RCC) treated with systemic chemotherapy followed by mammalian target of rapamycin inhibitor maintenance therapy. A 63-year-old male presented with lumbago, and lumbar vertebral tumors were detected by magnetic resonance imaging. Subsequent computed tomography (CT) revealed a right renal tumor and CT-guided biopsy of the right renal and left sacroiliac tumors determined pure sarcomatoid carcinoma without a clear cell component. Two cycles of combination chemotherapy comprising of gemcitabine (1,500 mg/m2 on day one) and doxorubicin (50 mg/m2 on day one) resulted in a 20% reduction in the longest diameter of the right renal tumor. However, due to grade 3 neutropenia, the chemotherapy was discontinued and temsirolimus (25 mg once weekly), which binds to the cytoplasmic protein, FKBP-12, and inhibits mTOR, was administered. Stable disease was maintained for 19 months with temsirolimus and no major adverse events, with the exception of grade 2 nausea, were observed. The patient succumbed to their disease at 30 months following the initiation of treatment. These results suggested that systemic chemotherapy followed by temsirolimus maintenance is a feasible treatment option for patients with metastatic sarcomatoid RCC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055997314

Download citation: RISBibTeXText

PMID: 24959297

DOI: 10.3892/ol.2014.2118


Related references

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. Anticancer Research 37(3): 1523-1528, 2017

Comparative efficacy of vascular endothelial growth factor VEGF tyrosine kinase inhibitor TKI and mammalian target of rapamycin mTOR inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE. 2012

Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 80(3-4): 214-218, 2011

Combination of gemcitabine and doxorubicin in sarcomatoid and/or rapidly progressive metastatic renal cell carcinoma (MRCC). 2007

Poster Combination of gemcitabine and doxorubicin in sarcomatoid and/or rapidly progressive metastatic renal cell carcinoma (Mrcc). European Journal of Cancer Suppl.s 5(4): 308-309, 2007

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Medical Oncology 29(5): 3291-3297, 2013

Treatment Algorithms in Metastatic Renal Cell Carcinoma, Including the Potential Role of the Novel Oral Mammalian Target of Rapamycin Inhibitor Everolimus. European Urology Suppl.s 8(10): 809-814, 2009

Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor. International Journal of Urology 21(7): 740, 2015

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Targeted Oncology 6(1): 5-16, 2011

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer 12(5): 335-340, 2015

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 34(14): 1660-1668, 2017

First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clinical Genitourinary Cancer 13(3): 210-217, 2016

Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors. Clinical Genitourinary Cancer 5(6): 359-361, 2007

Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Annals of PharmacoTherapy 45(1): 78-83, 2011

Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors. European Urology Suppl.s 8(10): 793-798, 2009